Liu, H., Wang, H., Shenvi, S., Hagen, T.M. and Liu, R.M. (2004) Glutathione Metabolism during Aging and in Alzheimer Disease. Annals of the New York Academy of Sciences, 1019, 346-349.
http://dx.doi.org/10.1196/annals.1297.059

has been cited by the following article:

• TITLE: Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study

  AUTHORS: Joaquín Lasierra-Cirujeda, María José Aza Pascual-Salcedo, María Mercedes Aza Pascual-Salcedo

  KEYWORDS: Sulodexide, Alzheimer’s Disease, Glutathione, t-PA, PAI-1, Plasminogen, Plasmin

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.6 No.2, February 24, 2016

  ABSTRACT: The purpose of this prospective study is to determine the relative incidence of Alzheimer’s disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer’s disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain.